AngioDynamics (ANGO) Tops Q3 EPS by 4c, Reaffirms FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance
April 7, 2022 7:00 AM EDTFiscal 2022 Third Quarter Highlights
Net sales of $74.0 million increased 3.9% compared to the prior-year quarter Med Tech grew 28.6% and Med Device declined 2.8% year over year Gross margin of 52.2% declined 190 basis points year over year GAAP loss per share of $0.13 and adjusted earnings per share of $0.03 Subsequent to quarter end: the Company enrolled the first patients in its PRESERVE study for the use of NanoKnife in prostate; the Company received FDA approval for its... More